Experimental drugs show potential to reverse multiple sclerosis damage

Researchers are advancing new therapeutic approaches to treat demyelinating conditions like multiple sclerosis by focusing on myelin repair rather than just preventing inflammation.

At the University of Colorado, scientists developed an experimental molecule, LL-341070, which acts as a thyroid hormone mimetic. In preclinical models, the compound boosted oligodendrocyte generation and accelerated the repair of myelin sheaths, leading to functional improvements in vision-related brain activity.

Separately, researchers at UVA Health have tested Kamuvudine K-9, a derivative of existing HIV drugs. In mouse models of multiple sclerosis, K-9 not only prevented further neurological deterioration but also reversed paralysis and vision loss. The drug helped preserve nerve fibers and halted the rise of neurofilament light chain, a biomarker of nerve damage. This research is supported by epidemiological data suggesting that certain HIV drugs, known as NRTIs, are associated with a significant reduction in the risk of developing multiple sclerosis and lower annual relapse rates.